Outlook Therapeutics, Inc. Research and Development Expense in USD from Q1 2015 to Q2 2025

Taxonomy & unit
us-gaap: USD
Description
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
Summary
Outlook Therapeutics, Inc. quarterly/annual Research and Development Expense history and growth rate from Q1 2015 to Q2 2025.
  • Outlook Therapeutics, Inc. Research and Development Expense for the quarter ending June 30, 2025 was $7.13M, a 36.3% decline year-over-year.
  • Outlook Therapeutics, Inc. Research and Development Expense for the twelve months ending June 30, 2025 was $33.7M, a 1.34% decline year-over-year.
  • Outlook Therapeutics, Inc. annual Research and Development Expense for 2024 was $41.8M, a 57.9% increase from 2023.
  • Outlook Therapeutics, Inc. annual Research and Development Expense for 2023 was $26.5M, a 37.5% decline from 2022.
  • Outlook Therapeutics, Inc. annual Research and Development Expense for 2022 was $42.3M, a 8.66% increase from 2021.
Research and Development Expense, Trailing 12 Months (USD)
Research and Development Expense, Quarterly (USD)
Research and Development Expense, YoY Quarterly Growth (%)
Research and Development Expense, Annual (USD)
Research and Development Expense, YoY Annual Growth (%)

Outlook Therapeutics, Inc. Quarterly Research and Development Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2025 $33.7M $7.13M -$4.07M -36.3% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-14
Q1 2025 $37.8M $4.41M -$9.1M -67.4% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-15
Q4 2024 $46.9M $9.66M +$5.13M +113% Oct 1, 2024 Dec 31, 2024 10-Q 2025-02-14
Q3 2024 $41.8M $12.5M +$7.58M +153% Jul 1, 2024 Sep 30, 2024 10-K 2024-12-27
Q2 2024 $34.2M $11.2M +$100K +0.9% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-14
Q1 2024 $34.1M $13.5M +$13M +2379% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-15
Q4 2023 $21.1M $4.53M -$5.33M -54.1% Oct 1, 2023 Dec 31, 2023 10-Q 2025-02-14
Q3 2023 $26.5M $4.94M -$4.05M -45% Jul 1, 2023 Sep 30, 2023 10-K 2024-12-27
Q2 2023 $30.5M $11.1M -$148K -1.31% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-14
Q1 2023 $30.6M $545K -$11.7M -95.5% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
Q4 2022 $42.3M $9.86M -$10.1K -0.1% Oct 1, 2022 Dec 31, 2022 10-Q 2024-02-14
Q3 2022 $42.3M $8.99M -$945K -9.51% Jul 1, 2022 Sep 30, 2022 10-K 2023-12-22
Q2 2022 $43.3M $11.2M +$2.7M +31.6% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 $40.6M $12.2M +$3.69M +43.3% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q4 2021 $36.9M $9.87M -$2.08M -17.4% Oct 1, 2021 Dec 31, 2021 10-Q 2023-02-14
Q3 2021 $39M $9.93M +$2.31M +30.3% Jul 1, 2021 Sep 30, 2021 10-K 2022-12-29
Q2 2021 $36.6M $8.55M +$57.1K +0.67% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-10
Q1 2021 $36.6M $8.53M +$4.15M +94.6% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-13
Q4 2020 $32.4M $11.9M +$6.1M +104% Oct 1, 2020 Dec 31, 2020 10-Q 2022-02-14
Q3 2020 $26.3M $7.62M +$168K +2.25% Jul 1, 2020 Sep 30, 2020 10-K 2021-12-23
Q2 2020 $26.2M $8.49M +$4.15M +95.5% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-13
Q1 2020 $22M $4.38M -$1.55M -26.2% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-14
Q4 2019 $23.6M $5.85M -$224K -3.69% Oct 1, 2019 Dec 31, 2019 10-Q 2021-02-16
Q3 2019 $23.8M $7.46M +$306K +4.28% Jul 1, 2019 Sep 30, 2019 10-K 2020-12-23
Q2 2019 $23.5M $4.34M -$1.45M -25.1% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-14
Q1 2019 $25M $5.94M +$779K +15.1% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-15
Q4 2018 $24.2M $6.07M +$5.67M +1409% Oct 1, 2018 Dec 31, 2018 10-Q 2020-02-14
Q3 2018 $18.5M $7.15M +$4.84M +210% Jul 1, 2018 Sep 30, 2018 10-K 2019-12-19
Q2 2018 $13.7M $5.8M +$1.64M +39.4% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-14
Q1 2018 $12M $5.16M +$1.04M +25.3% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-15
Q4 2017 $11M $402K -$12.8M -97% Oct 1, 2017 Dec 31, 2017 10-Q 2019-02-14
Q3 2017 $23.8M $2.31M -$1.57M -40.4% Jul 1, 2017 Sep 30, 2017 10-K 2018-12-18
Q2 2017 $25.4M $4.16M -$7.86M -65.4% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-14
Q1 2017 $33.2M $4.12M -$21.4K -0.52% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-15
Q4 2016 $33.3M $13.2M +$494K +3.88% Oct 1, 2016 Dec 31, 2016 10-Q 2018-02-14
Q3 2016 $32.8M $3.87M Jul 1, 2016 Sep 30, 2016 10-K 2017-12-29
Q2 2016 $12M +$2.34M +24.1% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-14
Q1 2016 $4.14M -$6.02M -59.2% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-15
Q4 2015 $12.7M Oct 1, 2015 Dec 31, 2015 10-Q 2017-02-14
Q2 2015 $9.68M Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-15
Q1 2015 $10.2M Jan 1, 2015 Mar 31, 2015 10-Q 2016-06-27

Outlook Therapeutics, Inc. Annual Research and Development Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $41.8M +$15.3M +57.9% Oct 1, 2023 Sep 30, 2024 10-K 2024-12-27
2023 $26.5M -$15.9M -37.5% Oct 1, 2022 Sep 30, 2023 10-K 2024-12-27
2022 $42.3M +$3.37M +8.66% Oct 1, 2021 Sep 30, 2022 10-K 2023-12-22
2021 $39M +$12.6M +47.9% Oct 1, 2020 Sep 30, 2021 10-K 2022-12-29
2020 $26.3M +$2.54M +10.7% Oct 1, 2019 Sep 30, 2020 10-K 2021-12-23
2019 $23.8M +$5.3M +28.6% Oct 1, 2018 Sep 30, 2019 10-K 2020-12-23
2018 $18.5M -$5.31M -22.3% Oct 1, 2017 Sep 30, 2018 10-K 2019-12-19
2017 $23.8M -$8.95M -27.3% Oct 1, 2016 Sep 30, 2017 10-K 2018-12-18
2016 $32.8M -$6.11M -15.7% Oct 1, 2015 Sep 30, 2016 10-K 2017-12-29
2015 $38.9M Oct 1, 2014 Sep 30, 2015 10-K 2016-12-29
* An asterisk sign (*) next to the value indicates that the value is likely invalid.